Dialog Box

Loading...
mEOC for Mucinous Ovarian Cancer

Trial Name: mEOC: A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer (mEOC).

 

Patients Involved:

  • Patients with advanced mucinous Epithelial Ovarian Cancer
  • Recurrent FIGO Stage I or newly diagnosed FIGO Stage II-IV (without brain mets)
  • Patients must be chemonaive

 

Treatment Given:

  • Arm 1: Carboplatin AUC5/6, Paclitaxel 175mg/m2 - 6 cycles, 21 days.
  • Arm 2: Oxaliplatin 130 mg/m2, Capecitabine 850mg/m2 bd (given for 14 days) - 6 cycles, 21 days.
  • Arm 3: Carboplatin AUC5/6, Paclitaxel 175mg/m2, Bevacizumab (15mg/kg) - 6 cycles, 21 days.
  • Followed by Bevacizumab maintenance 12 cycles, 21 days.
  • Arm 4: Oxaliplatin 130 mg/m2, Capecitabine 850mg/m2 bd (given for 14 days) , Bevacizumab (15mg/kg) - 6 cycles, 21 days.
  • Followed by Bevacizumab maintenance 12 cycles, 21 days.

 

Rationale for Treatment: Advanced mEOC is an extremely rare form of ovarian cancer. Histopathologically it has many similarities with upper GI cancer and molecularly, it differs from common forms of EOC. In addition, it does not respond to standard ovarian cancer chemotherapy as well as other histological subtypes. For this reason, this study examines whether a standard GI regimen may be of more benefit to patients with mEOC. There is very little research that focuses on the treatment of this condition in the UK or indeed elsewhere.

 

This trial is compares the effectiveness of capecitabine and oxaliplatin with the standard treatment for ovarian cancer, carboplatin and paclitaxel. The trial will also determine whether the addition of Bevacizumab, an anti-VEGF therapy, to chemotherapy improves survival.

 

Recruitment and sites involved: The trial opened in January 2010. There are currently 39 sites in the UK, and 2 sites in Finland. To date 20 of the target 332 patients required have joined the trial. The recruitment period is due to end in October 2013.

 

For further information please go to:

 

 

Any trial correspondence should be directed to the mEOC study team via e-mail ctc.mEOC@ucl.ac.uk.